menu
    • menu
    [{"orgOrder":0,"company":"MindImmune Therapeutics","sponsor":"Wheeler Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"MITI-101","moa":"CD11c","graph1":"Neurology","graph2":"IND Enabling","graph3":"MindImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindImmune Therapeutics \/ MindImmune Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"MindImmune Therapeutics \/ MindImmune Therapeutics"},{"orgOrder":0,"company":"MindImmune Therapeutics","sponsor":"Dolby Family Ventures | Pfizer Ventures | Gates Frontier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Series A Financing","leadProduct":"MITI-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"MindImmune Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"MindImmune Therapeutics \/ Dolby Family Ventures | Pfizer Ventures | Gates Frontier","highestDevelopmentStatusID":"4","companyTruncated":"MindImmune Therapeutics \/ Dolby Family Ventures | Pfizer Ventures | Gates Frontier"}]

    Find Clinical Drug Pipeline Developments & Deals by MindImmune Therapeutics

    Menu

    MindImmune Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MindImmune Therapeutics

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed

                            MindImmune Therapeutics

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MITI-101

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Dolby Family Ventures | Pfizer Ventures | Gates Frontier

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            MindImmune Raises $30M for Alzheimer’s Therapy, Names Isaac Stoner CEO

                            Details : The Series A financing round will support the development of MITI-101, an unconjugated antibody, to address undisclosed key focus areas in biomedicine.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            November 24, 2025

                            Lead Product(s) : MITI-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Dolby Family Ventures | Pfizer Ventures | Gates Frontier

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MindImmune Therapeutics

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed

                            MindImmune Therapeutics

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MITI-101

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Recipient : Wheeler Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Wheeler Bio and MindImmune Therapeutics Sign CDMO Partnership Agreement

                            Details : Wheeler Bio will provide integrated process development and cGMP drug substance manufacturing services via its ModularCMC™ platform to support the advancement of the MITI-101 program.

                            Product Name : MITI-101

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 17, 2025

                            Lead Product(s) : MITI-101

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Recipient : Wheeler Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.